Upgrade subject to access all content
Enzymes can be targeted for inhibition directly at their active sites (orthogonal targeting) or at secondary/allosteric sites.
Which of the following is NOT considered a benefit of allosteric targeting?
It is easier to develop allosteric inhibitors.
There are more allosteric sites compared to orthogonal ones for any given protein.
Allosteric sites tend to be unique to the specific enzyme in question.
Incorrect dosing for an orthogonal inhibitor can lead to severe health/toxicity issues.